| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|
| Net income | 163,749 | 66,950 | 50,806 |
| Depreciation and amortization | 15,343 | 10,340 | 5,092 |
| Gain on warrant liability | - | 0 | 0 |
| Loss on warrant liability | 0 | - | - |
| Impairment of assets | 0 | 0 | - |
| Impairment of goodwill | 0 | 0 | - |
| Derecognition of goodwill | 0 | 0 | - |
| Stock-based compensation expense | 119,606 | 106,389 | 27,642 |
| Changes to deferred taxes | 22,942 | -4,865 | -2,500 |
| Debt accretion expense | 756 | 504 | 253 |
| (increase)/decrease in accounts receivable-Nonrelated Party | 154,960 | 116,768 | 62,633 |
| (increase)/decrease in accounts receivable-Related Party | 3,751 | 2,135 | 656 |
| (increase)/decrease in inventories | 308 | -575 | 268 |
| (increase)/decrease in income tax receivable | 12,097 | - | - |
| (increase)/decrease in prepaid expenses and other current assets | 6,376 | 8,640 | 1,378 |
| (increase)/decrease in operating right-of-use assets | 518 | 121 | 406 |
| Increase/(decrease) in accounts payable-Nonrelated Party | 36,637 | 19,334 | 10,222 |
| Increase/(decrease) in accounts payable-Related Party | 3,276 | 1,169 | 1,334 |
| Increase/(decrease) in operating lease liabilities | -164 | 194 | -245 |
| Increase/(decrease) in accrued arbitration expenses | -16,571 | -21,043 | -4,061 |
| Increase/(decrease) in accrued income tax expense | -26,533 | -18,169 | 19,598 |
| Increase/(decrease) in accrued expenses and other current liabilities | 2,527 | 2,180 | -769 |
| Net cash provided by operating activities | 177,736 | 78,222 | 50,965 |
| Acquisitions of property and equipment | 1,117 | 815 | 64 |
| Proceeds from restricted short-term investment | 2,941 | 2,941 | - |
| Cash related to sale of business | 0 | 0 | - |
| Cash related to asset acquisition | 1,994 | 1,994 | - |
| Net cash used in investing activities | -170 | 132 | -64 |
| Proceeds from lines of credit | 5,043 | 4,606 | 3,864 |
| Proceeds from long-term debt | - | - | 157 |
| Proceeds from notes payable | 273 | 258 | - |
| Repayments of lines of credit | 3,293 | 301 | 292 |
| Repayments of long-term debt | - | - | 1,810 |
| Repayments of notes payable | 8,319 | 5,697 | - |
| Repayments of finance leases | 4,004 | 2,593 | 1,367 |
| Proceeds from common stock issuance, net issuance costs | 0 | 0 | 0 |
| Proceeds from exercise of warrants | 0 | - | - |
| Members' contributions | 316 | 242 | - |
| Members' distributions | 42,174 | 18,776 | 7,364 |
| Net cash provided by (used in) financing activities | -52,158 | -22,261 | -6,812 |
| Net increase in cash and cash equivalents | 125,408 | 56,093 | 44,089 |
| Cash and cash equivalents at beginning of period | 40,640 | 40,640 | 40,640 |
| Cash and cash equivalents at end of period | 166,048 | 96,733 | 84,729 |
Nutex Health, Inc. (NUTX)
Nutex Health, Inc. (NUTX)